Why a $480,000-a-Year Pancreatic Cancer Pill Just Doubled Survival — and Who Can Actually Get It

For roughly a decade, metastatic pancreatic cancer has been a near-certain death sentence within a year. On August 26, 2026, the FDA approved daraxonrasib (brand name Rasonque) for adults with KRAS G12C-mutated pancreatic cancer that has spread or cannot be removed surgically. In the pivotal trial, patients who got the pill lived about twice as long as those on chemotherapy (New York Times, 2026). The list price, however, lands near $480,000 a year. Here is what changed, who qualifies, and how to think about the cost.

Key Takeaways

• On August 26, 2026 the FDA approved daraxonrasib, the first KRAS-targeted pill for pancreatic cancer, after a trial showed patients lived roughly twice as long as those on chemotherapy (FDA, 2026).
• About 1 percent of pancreatic cancers carry the KRAS G12C mutation the drug targets, so genetic testing of the tumor is required before starting therapy (FDA, 2026).
• The launch price of about $480,000 per year puts daraxonrasib among the most expensive cancer pills ever launched, and the Institute for Clinical and Economic Review has questioned whether it is fairly priced (ICER, 2026).
• The drug is oral, taken daily, and approved after at least one prior line of therapy, which puts it later in the treatment course for most patients.

What Just Happened

On August 26, 2026, the FDA approved daraxonrasib for adults with KRAS G12C-mutated pancreatic cancer that has spread or cannot be removed surgically and who have already received at least one systemic therapy (FDA, 2026). The approval came roughly six weeks ahead of the agency's decision deadline and was based on a single-arm phase 2 trial in which patients lived a median of about twice as long as historical chemotherapy controls (New York Times, 2026).

Citation capsule: The FDA approved daraxonrasib on August 26, 2026 for KRAS G12C-mutated metastatic pancreatic cancer after a phase 2 trial showed roughly double the survival of chemotherapy controls (FDA, 2026).

For background on KRAS-driven cancers and the wider KRAS pipeline, see our colon cancer screening update — it covers how DNA testing has become routine at diagnosis.

Who Actually Qualifies

Daraxonrasib is approved only for the subset of patients whose tumor carries a KRAS G12C mutation. About 1 percent of pancreatic cancers fit that profile, so the practical question is whether the patient's tumor has been sequenced (FDA, 2026). For most U.S. patients diagnosed today, next-generation sequencing of the tumor is standard and usually covered, but it is worth confirming.

Eligibility criterion	What it means
Tumor type	Pancreatic adenocarcinoma confirmed by pathology
Mutation	KRAS G12C documented by an FDA-approved companion diagnostic
Stage	Metastatic disease, or locally advanced and not surgically resectable
Prior therapy	At least one prior systemic line of therapy
Performance status	Adequate organ function and ability to take an oral drug daily

Citation capsule: Daraxonrasib is restricted to KRAS G12C-mutated tumors — roughly a about 1 percent of pancreatic cancers — and requires documentation by an FDA-approved companion diagnostic (FDA, 2026).

If you or a family member is being evaluated, two questions matter: (1) Has comprehensive genomic profiling been run on the tumor or a recent biopsy? (2) Is there a documented KRAS G12C result? Without those, the drug cannot be prescribed.

How Daraxonrasib Works

KRAS is a small protein that acts as a molecular switch, telling cells when to grow and when to stop. Mutations like G12C lock the switch in the "on" position, which drives uncontrolled division. Daraxonrasib binds to a hidden pocket on the mutant KRAS protein that only exists when the switch is in its "off" state, locking it off and slowing tumor growth (Revolution Medicines, 2026).

Citation capsule: Daraxonrasib binds a cryptic pocket on mutant KRAS G12C and traps the protein in its inactive state, blocking growth signaling (Revolution Medicines, 2026).

The drug is taken as a tablet once daily, with or without food, until disease progression or unacceptable side effects. Common side effects include nausea, diarrhea, fatigue, and liver-test elevations; less commonly, serious lung inflammation (FDA, 2026). For background on how oral cancer drugs fit into the wider pharmaceutical market, see our generic drug shortages guide.

Why the $480,000 Price Matters

Daraxonrasib's wholesale acquisition cost is about $480,000 per year, putting it among the most expensive oral cancer therapies ever launched (New York Times, 2026). The Institute for Clinical and Economic Review, which evaluates whether new drugs are fairly priced, has signaled that at this cost, daraxonrasib exceeds commonly accepted cost-effectiveness thresholds for pancreatic cancer.

Citation capsule: At a launch price of roughly $480,000 per year, daraxonrasib is among the most expensive cancer pills ever introduced, prompting fair-price concerns from cost-effectiveness reviewers (ICER, 2026).

What this means in practice:

• Commercial insurance: covered under the medical benefit, not the pharmacy benefit, because it is an oral oncology drug. Out-of-pocket exposure depends on the plan's specialty drug tier.
• Medicare Part D: covered, but enrollees in 2026 still face the new $2,000 annual out-of-pocket cap under the Inflation Reduction Act, which limits the worst exposure.
• Medicaid: required to cover, but net price after mandatory rebates is often substantially lower than list.
• Manufacturer assistance: Revolution Medicines has a copay assistance program for commercially insured patients; Medicare and Medicaid beneficiaries are excluded by federal anti-kickback rules.

For context on the broader drug-pricing landscape, including the most-favored-nation deals that have quietly lowered some new-drug prices, see our PBM reform guide and our ways to cut prescription costs.

What This Means for the Wider KRAS Pipeline

Daraxonrasib is the first KRAS inhibitor approved for pancreatic cancer, but it is unlikely to be the last. More than a dozen KRAS inhibitors are in clinical development, including G12D and G12V inhibitors that would each address a different slice of pancreatic tumors (New York Times, 2026). The approval matters not because it is a cure — it is not — but because it confirms that KRAS, long considered "undruggable," has a workable foothold.

Citation capsule: More than a dozen KRAS-targeted drugs are in clinical trials, including agents against G12D and G12V mutations that together account for the majority of pancreatic cancers (New York Times, 2026).

For patients with the more common G12D or G12V pancreatic mutations, clinical trials may be the fastest path to a similar drug — oncology trial databases such as ClinicalTrials.gov can be filtered by mutation and tumor type.

Frequently Asked Questions

Is daraxonrasib a cure for pancreatic cancer?

No. The drug is approved for advanced disease and the trial showed it doubled median survival, not that it eliminated the cancer. Median survival on daraxonrasib was about a year compared with roughly six months for chemotherapy controls (New York Times, 2026).

How do I know if I have the KRAS G12C mutation?

Your oncologist orders comprehensive genomic profiling on the tumor tissue or a recent biopsy. The result is typically returned in two to three weeks. About 1 percent of pancreatic adenocarcinomas carry this specific mutation.

Will insurance cover a $480,000-a-year drug?

Coverage varies. Medicare Part D caps annual out-of-pocket at $2,000 in 2026. Commercial plans usually cover it after prior authorization, with copays determined by the plan's specialty tier. Manufacturer copay assistance is available for commercially insured patients but not for those on federal programs.

Are there clinical trials for the more common KRAS mutations?

Yes. Several G12D- and G12V-targeted drugs are in phase 1 and 2 trials. ClinicalTrials.gov can be filtered by mutation, tumor type, and geography.

Conclusion

Daraxonrasib's approval is a meaningful step for a small group of patients with one of the deadliest cancers, and the start of a wider KRAS pipeline that may reach more patients over the next few years. The price tag is a real barrier, but coverage pathways, the new $2,000 Medicare cap, and ongoing clinical trials give patients concrete next steps. If a pancreatic cancer diagnosis is recent, ask the oncology team whether comprehensive genomic profiling has been performed, and confirm whether the result includes KRAS subtyping.

Sources

• U.S. Food & Drug Administration. FDA approves daraxonrasib for KRAS G12C-mutated pancreatic cancer. August 26, 2026. https://www.fda.gov
• Kolata G, Robbins R, Johnson CY. F.D.A. Approves the Drug Daraxonrasib That's Poised to Transform Pancreatic Cancer. New York Times. August 26, 2026. Retrieved September 2, 2026. https://www.nytimes.com/2026/08/26/science/pancreatic-cancer-daraxonrasib-approval.html
• Robbins R, Johnson CY. New Drug Approved by F.D.A. for Pancreatic Cancer Could Be First of Many. New York Times. August 27, 2026. Retrieved September 2, 2026. https://www.nytimes.com/2026/08/27/science/pancreatic-cancer-drug-fda-testing.html
• Robbins R. A $480,000-a-Year Pill Reflects a New Normal for Cancer Drugs. New York Times. August 31, 2026. Retrieved September 2, 2026. https://www.nytimes.com/2026/08/31/business/pancreatic-cancer-drug-prices.html
• Institute for Clinical and Economic Review. Daraxonrasib in pancreatic cancer: fair price analysis. 2026.
• Revolution Medicines. Daraxonrasib mechanism of action. 2026. https://www.revmed.com